Aspirin, salicylates, and cancer

The Lancet

Volumn 373, Issue 9671, 2009, Pages 1301-1309

  Elwood, Peter C ^a   Gallagher, Alison M ^b   Duthie, Garry G ^c   Mur, Luis AJ ^d   Morgan, Gareth ^e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c ROWETT RESEARCH INSTITUTE   (United Kingdom)

^d ABERYSTWYTH UNIVERSITY   (United Kingdom)

^e Welsh Aspirin Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE;

BLADDER CANCER; BRAIN HEMORRHAGE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; DIETARY INTAKE; DRUG DOSE REDUCTION; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; HUMAN; LARGE INTESTINE CANCER; LUNG CANCER; MOUTH CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; SKIN CANCER; STOMACH CANCER; STOMACH HEMORRHAGE;

EID: 64049106907     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60243-9     Document Type: Review

References (116)

1. Gasic G.J., Gasic T.B., and Stewart C.C. Anti-metastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61 (1968) 46-52
2. Gasic G.J., Gasic T.B., and Murphy S. Anti-metastatic effect of aspirin. Lancet 2 (1972) 932-933
3. Kolenich J.J., Mansour E.G., and Flynn A. Haematological effects of aspirin. Lancet 2 (1972) 714
4. Jaffe B.M. Prostaglandin and cancer: an update. Prostaglandins 6 (1974) 453-461
5. Bennett A., and Del Tacca M. Proceedings: prostaglandins in human colonic carcinoma. Gut 16 (1975) 409
6. Kune G.A., Kune S., and Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48 (1988) 4399-4404
7. IARC Handbooks of cancer prevention. Non-steroidal anti-inflammatory drugs vol 1 (1997), International Agency for Research on Cancer, Lyon
8. Vainio H., Morgan G., and Kleihues P. An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 6 (1997) 749-753
9. Baron J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37 (2003) 1-24
10. Mahdi J.G., Alkarrawi M.A., Mahdi A.J., Bowen I.D., and Humam D. Calcium salicylate-mediated apoptosis in human HT01080 fibrosarcoma cells. Cell Prolif 39 (2006) 249-260
11. Gann P.H., Manson J.E., Glyn R.J., Buring J.E., and Hennekens C.H. Low-dose aspirin and incidence of colorectal tumors in a randomised trial. J Natl Cancer Inst 85 (1993) 1220-1224
12. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988) 313-316
13. Cook N.R., Lee I.M., Gaziano J.M., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomised controlled trial. JAMA 294 (2005) 47-55
14. Zhang S.M., Cook N.R., Manson J.E., Lee I.M., and Buring J.E. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98 (2008) 989-991
15. Giovannucci E., Egan K.M., Hunter D.J., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333 (1995) 609-614
16. Collet J.P., Sharpe C., Belzile E., Boivin J.F., Hanley J., and Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81 (1999) 62-68
17. Harris R.E., Chlebowski R.T., Jackson R.D., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63 (2003) 6096-6101
18. Chan A.T., Manson J.E., Feskanich D., Stampfer M.J., Colditz G.A., and Fuchs C.S. Long-term aspirin use and mortality in women. Arch Intern Med 167 (2007) 562-572
19. Flossmann E., Rothwell P.M., and on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 (2007) 1603-1613
20. Sandler R.S., Halabi S., Baron J.A., et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 (2003) 883-890
21. Baron J.A., Cole B.F., Sandler R.S., et al. A randomised trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
22. Smith G.D., and Ebrahim S. Mendelian randomisation: prospects, potential and limitations. Int J Epidemiol 33 (2004) 30-42
23. Lin H.J., Lakkides K.M., Keku T.O., et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11 (2002) 1305-1313
24. Powles T.J., Clark S.A., Easty D.M., Easty G.C., and Neville A.M. The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer 28 (1973) 316-321
25. Rao C.V., Rivenson A., Simi B., et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res 55 (1995) 1462-1472
26. Barnes C.J., and Lee M. Chemoprotection of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterol 114 (1998) 873-877
27. Reddy B.S., Kawamori T., Lubet R., Steele V., Kelloff G., and Rao C.V. Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis 20 (1999) 1645-1648
28. Miliaras S., Miliaras D., Vrettou E., Zavitsanakis A., and Kiskinis D. The effect of aspirin and high fibre diet on colorectal carcinoma: a comparative experimental study. Tech Coloproctol 8 suppl 1 (2004) S59-S61
29. Thun M.J., Henley S.J., and Patrona C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
30. Mathers J.C., Mickleburgh I., Chapman P.C., et al. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 study. Proc Nutr Soc 62 (2003) 51-57
31. Garcia Rodriguez L.A., and Huerta-Alvarez C. Reduced incidence of colorectal adenomas among long term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11 (2000) 376-381
32. Bosetti C., Gallus S., and La Vecchia C. Aspirin and cancer risk: an update quantitative review to 2005. Cancer Causes Control 17 (2006) 871-888
33. Asano T.K., and McLeod R.S. Non-steroidal anti-inflammatory drugs and aspirin for the prevention of colo-rectal adenomas and cancer: a systematic review. Dis Colon Rectum 47 (2004) 665-673
34. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
35. Jacobs E.J., Thun M.J., Bain E.B., Rodriguez C., Henley S.J., and Calle E.E. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99 (2007) 608-615
36. Khuder S.A., and Mutgi A.B. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84 (2001) 1188-1192
37. González-Pérez A., García Rodríguez L.A., and López-Ridaura R. Effects of non-steroidal anti inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3 (2003) 28
38. Agrawal A., and Fentiman I.S. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62 (2008) 444-449
39. Friis S., Nielsen G.L., Mellemkjaer L., et al. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97 (2002) 96-101
40. Ruffin IV M.T., Krishnan K., Rock C.L., et al. Suppression of colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89 (1997) 1152-1160
41. Terry M.B., Gammon M.D., Zhang F.F., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291 (2004) 2433-2440
42. Jacobs E.J., Rodriguez C., Mondul A.M., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97 (2005) 975-980
43. Smalley W., Ray W.A., Daugherty J., and Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159 (1999) 161-166
44. Pierpoint W.S. The natural plant product and mammalian tissue. Interdiscip Sci Rev 22 (1997) 45-52
45. Baxter G.J., Graham A.B., Lawrence J.R., Wiles D., and Paterson J.R. Salicylic acid in soups prepared from organically and non-organically grown vegetables. Eur J Nutr 40 (2001) 289-292
46. Robertson G.L., and Kermode W.J. Salicylic acid in fresh and canned fruit and vegetables. J Sci Food Agric 32 (1981) 833-836
47. Swain A.R., Dutton S.P., and Truswell A.S. Salicylates in foods. J Am Diet Assoc 85 (1985) 950-960
48. Paterson J.R., Srivastava R., Baxter G.J., Graham A.B., and Lawrence J.R. Salicylic acid content of spices and its implications. J Agric Food Chem 54 (2006) 2891-2896
49. Curtis M.J., and Wolpert T.J. The victorin-induced mitochondrial permeability transition precedes cell shrinkage and biochemical markers of cell death, and shrinkage occurs without loss of membrane integrity. Plant J 38 (2004) 244-259
50. Neill S.J., Desikan R., Clarke A., Hurst R.D., and Hancock J.T. Hydrogen peroxide and nitric oxide as signalling molecules in plants. J Exp Bot 53 (2002) 1237-1247
51. Mur L.A., Brown I.R., Darby R.M., et al. A loss of resistance to avirulent bacterial pathogens in tobacco is associated with the attenuation of a salicylic acid-potentiated oxidative burst. Plant J 23 (2000) 609-621
52. Mehdy M.C. Active oxygen species in plant defense against pathogens. Plant Physiol 105 (1994) 467-472
53. Lamb C., and Dixon R.A. The oxidative burst in plant disease resistance. Ann Rev Plant Physiol Plant Mol Biol 48 (1997) 251-275
54. Chung Y.M., Bae Y.S., and Lee S.Y. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic Biol Med 34 (2003) 434-442
55. Norman C., Howell K.A., Millar A.H., Whelan J.M., and Day D.A. Salicylic acid is an uncoupler and inhibitor of mitochondrial electron transport. Plant Physiol 134 (2004) 492-501
56. Battaglia V., Salvi M., and Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J Biol Chem 280 (2005) 33864-33872
57. Genkinger J.M., Platz E.A., Hoffman S.C., Comstock G.W., and Helzlsouer K.J. Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. Am J Epidemiol 160 (2004) 1223-1233
58. Paterson J.R., and Lawrence J.R. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. QJM 94 (2001) 445-448
59. Janssen P.L., Katan M.B., Staveren W.A., Hollman P.C., and Venema D.P. Acetylsalicylic and salicylates in foods. Cancer Lett 114 (1997) 163-164
60. Blacklock C.J., Lawrence D., Wiles D., et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians and patients taking low-dose aspirin. J Clin Pathol 54 (2001) 553-555
61. Lawrence J.R., Peter R., Baxter G.J., Robson J., Graham A.B., and Paterson J.R. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J Clin Pathol 56 (2003) 651-653
62. Hawk E.T., Umar A., and Viner J.L. Colorectal cancer chemoprevention-an overview of the science. Gastroenterol 126 (2004) 1423-1447
63. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta 1299 (1996) 125-140
64. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
65. Chell S., Kadi A., Williams A.C., and Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of cancer. Biochim Biophys Acta 1766 (2006) 104-119
66. Wang D., and DuBois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
67. Morita I., Schindler M., Regier M.K., et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 270 (1995) 10902-10908
68. Gonzalez E.R., and Kannewurf B.S. Atherosclerosis: a unifying disorder with diverse manifestations. Am J Health Syst Pharm 55 (1998) S4-S7
69. Xu X.M., Sansores-Garcia L., Chen X.M., Matijevic-Aleksic N., Du M., and Wu K.K. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96 (1999) 5292-5297
70. Wu K.K. Aspirin and salicylate: an old remedy with a new twist. Circulation 102 (2000) 2022-2023
71. Paterson T.J., Baxter G., Lawrence J., and Duthie G. Is there a role for dietary salicylates in health?. Proc Nutr Soc 65 (2006) 93-96
72. Featherstone C. Aspirin for bowel cancer: an old friend finds a new role. Lancet 350 (1997) 418
73. Janne P.A., and Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 342 (2000) 1960-1968
74. Fiorucci S., Antonelli E., and Morelli A. Mechanism of non-steroidal anti-inflammatory drug gastropathy. Dig Liver Dis 33 Suppl 2 (2001) S35-S43
75. Hong W.K., and Sporn M.B. Recent advances in chemoprevention of cancer. Science 278 (1997) 1073-1077
76. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70 (2005) 969-986
77. Shureiqi I., Xu X., Chen D., et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 61 (2001) 4879-4884
78. Zhang Z., and DuBois R.N. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterol 118 (2000) 1012-1017
79. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
80. Bellosillo B., Pique M., Barragan M., et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukaemia cells. Blood 92 (1998) 1406-1414
81. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik Y., and Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen activated protein kinase but inhibits tumour necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 94 (1997) 2869-2873
82. Zimmermann K.C., Waterhouse N.J., Goldstein J.C., Schuler M., and Green D.R. Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia 2 (2000) 505-513
83. Chan T.A., Morin P.J., Vogelstein B., and Kinzler K.W. Mechanisms underlying non-steroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95 (1998) 681-686
84. Zhou X.M., Wong B.C., Fan X.M., et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 22 (2001) 1393-1397
85. Stark L.A., Din F.V., Zwacka R.M., and Dunlop M.G. Aspirin induced activation of the NF-kappa B signalling pathway; a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15 (2001) 1273-1275
86. Din F.V., Dunlop M.G., and Stark L.A. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 91 (2004) 381-388
87. Rigas B., and Shiff S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54 (2000) 210-215
88. Charames G.S., and Bapat B. Genomic instability and cancer. Curr Mol Med 3 (2003) 589-596
89. Modrich P. DNA mismatch correction. Ann Rev Biochem 56 (1987) 435-466
90. Liu B., Farrington S.M., Petersen G.M., et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1 (1995) 348-352
91. Kolodner R.D. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 20 (1995) 397-401
92. Grady W.M. Genomic instability and colon cancer. Cancer Metastasis Rev 23 (2004) 11-27
93. Ruschoff J., Wallinger S., Dietmaier W., et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95 (1998) 11301-11306
94. Goel A., Chang D.K., Ricciardiello L., Gasche C., and Boland C.R. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 9 (2003) 383-390
95. Nunez L., Valero R.A., Senovilla L., Sanz-Blasco S., Garcia-Sancho J., and Villalobos C. Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J Physiol 571 (2006) 57-73
96. Drew J.E., Arthur J.R., Farquharson A.J., Russell W.R., Morrice P.C., and Duthie G.G. Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon. Biochem Pharmacol 70 (2005) 888-893
97. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncology Rep 13 (2005) 559-583
98. Borthwick G.M., Johnson A.S., Partington M., Burn J., Wilson R., and Arthur H.M. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a COX-independent mechanism. FASEB J 20 (2006) 2009-2016
99. Jankowski J., and Moayyedi P. Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96 (2004) 885-887
100. Lanas A., Fuentes J., Benito R., Serrano P., Bajador E., and Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
101. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
102. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeparazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
103. Office for National Statistics: The health of the nation. Series DS, vol 2, decennial supplement no 13 (2000), Office for National Statistics, London, UK
104. Iwama T., and Mishima Y. Mortality in young first degree relatives of patients with familial adenomatous polyposis. Cancer 73 (1994) 2065-2068
105. Williams A.R., Balasooriya B.A., and Day D.W. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 23 (1982) 835-842
106. Marcus A.J. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 333 (1995) 656-657
107. Elder D.J., Hague A., Hicks D.J., and Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumour cell lines: enhanced apoptosis in carcinoma and in-vitro transformed adenoma relative to adenoma cell lines. Cancer Res 56 (1996) 2273-2276
108. Jacobs E.J., and Thun M.J. Low-dose aspirin and vitamin E: challenges and opportunities in cancer prevention. JAMA 294 (2005) 105-106
109. Flossman E., and Rothwell P.M. Commentary: aspirin and colorectal cancer-an epidemiological success story. Int J Epidemiol 36 (2007) 962-965
110. Jolly K., Cheng K.K., and Langman M.J. NSAIDs and gastrointestinal cancer prevention. Drugs 62 (2002) 945-956
111. Sanmuganathan P.S., Gjahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
112. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
113. Garcia Rodriquez L.A., Hernandez-Dias S., and de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiological studies. Br J Clin Pharmacol 52 (2001) 563-571
114. Hernandez-Dias S., and Rodriquez L.A. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiological studies. J Clin Epidemiol 55 (2002) 157-163
115. He J., Whelton P.K., Vu B., and Klag M.J. Aspirin and risk of haemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 280 (1998) 1930-1935
116. Kassirer J.P. Incorporating patients' preferences into medical decisions. N Engl J Med 330 (1994) 1895-1896